To date, some assays to detect urinary DNA TERT promoter mutations for bladder cancer early screening were established, most of them involve the use of next‐generation sequencing (NGS) platform, but the capability of rapidly detecting TERT promoter mutations in the clinic is restricted by its GC‐rich region.26, 27, 28. This evidence concerns the gene TERT and urinary bladder carcinoma.